RHO and cancer: Cancer genome‐wide data have provided substantial evidence of abnormal expression and function of Rho, GEF, GAP, and effectors, but there is a lack of target validation in primary cancer cell lines and animal models, and existing tool molecules mostly remain at the proof‐of‐concept stage, leading to slow development of Rho GTPase‐related drugs [457].